Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Aluminium chloride hexahydrate
Dermal Laboratories Ltd
D10AX01
Aluminium chloride hexahydrate
200mg/1ml
Cutaneous solution
Cutaneous
No Controlled Drug Status
Valid as a prescribable product
BNF: 13120000; GTIN: 5016379105005
PACKAGE LEAFLET _Information for the user_ READ ALL OF THIS LEAFLET CAREFULLY BEFORE USING THIS PRODUCT. Keep this leaflet. You may need to read it again. Ask your doctor or pharmacist if you need more information or advice. IN THIS LEAFLET: 1. What Anhydrol Forte is and what it is used for 2. Before you use Anhydrol Forte 3. How to use Anhydrol Forte 4. Possible side effects 5. How to store Anhydrol Forte 6. Further information 1. WHAT ANHYDROL FORTE IS AND WHAT IT IS USED FOR • Anhydrol Forte is a treatment for excessive sweating (hyperhidrosis) of the armpits, hands or feet. • Anhydrol Forte is suitable for use by adults, children and the elderly. • The ACTIVE INGREDIENT in this product is aluminium chloride hexahydrate. It helps the product to: – reduce sweating by blocking sweat ducts in the skin, and – provide a deodorant action by killing the bacteria that cause body odour. 2. BEFORE YOU USE ANHYDROL FORTE DO NOT USE Anhydrol Forte if you are ALLERGIC (hypersensitive) to aluminium chloride hexahydrate or the other ingredient of Anhydrol Forte, industrial methylated spirit. TAKE SPECIAL CARE when using this product: • Only use it on the armpits, hands or feet. • Make sure that the treated areas are COMPLETELY DRY before applying the product (see Section 3 for advice on this). • Do not use on broken or irritated skin: – when treating the armpits, do not shave or use hair-removing products within 12 hours before or after applying Anhydrol Forte. • Keep it away from the eyes, nose and mouth. • AVOID SPILLAGE as this may cause damage to you, your clothing and your possessions (see Section 4): – do not shake the bottle. – do not attempt to remove the roller ball head. – keep the cap tightly closed when not in use. • The product is highly flammable. Do not use it near flames or ignition sources. UNDER ARM SHAVING/HAIR REMOVAL Do not shave or use hair removing products in the 12 hours before and after using Anhydrol Forte USING OTHER MEDICINES Anhydrol Forte is not known to affect or Read the complete document
OBJECT 1 ANHYDROL FORTE 20% W/V CUTANEOUS SOLUTION Summary of Product Characteristics Updated 10-Jun-2015 | Dermal Laboratories Limited 1. Name of the medicinal product ANHYDROL™ FORTE 20% w/v CUTANEOUS SOLUTION 2. Qualitative and quantitative composition Aluminium Chloride Hexahydrate 20.0% w/v. 3. Pharmaceutical form Clear, colourless evaporative cutaneous solution. 4. Clinical particulars 4.1 Therapeutic indications For the topical treatment of hyperhidrosis specifically involving axillae, hands or feet. 4.2 Posology and method of administration For adults, children and the elderly: Apply to the affected sites at night, as required, and allow to dry. Wash off in the morning. 4.3 Contraindications Not to be used in cases of sensitivity to any of the ingredients. 4.4 Special warnings and precautions for use Care should be taken to restrict the application to the affected sites only. Keep away from the eyes. Care should be taken to avoid Anhydrol Forte coming into direct contact with clothing, polished surfaces, jewellery or metal. Replace cap tightly after use. 4.5 Interaction with other medicinal products and other forms of interaction Do not bathe immediately before use and, if the axillae are treated, do not shave or use depilatories on this area within 12 hours before or after use. 4.6 Pregnancy and lactation No special precautions. 4.7 Effects on ability to drive and use machines None known. 4.8 Undesirable effects If applied too frequently, Anhydrol Forte may cause irritation which should be treated with a mild topical hydrocortisone cream. REPORTING OF SUSPECTED ADVERSE REACTIONS Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. 4.9 Overdose See section 4.8 above (undesirable effects). 5. Pharmacological properties 5.1 Pharmacodynamic prope Read the complete document